PRO*BPD: Effectiveness of outpatient treatment PROgrammes for Borderline Personality Disorder: A comparison of Schema Therapy and Dialectical Behaviour Therapy

Conditions

F60.31

Assmann N, Kaiser T, Herzog P, Arntz A, Klein JP, Fassbinder E, Schaich A.

2025-10-23

10.1016/j.brat.2025.104899

Differential effectiveness of dialectical behavioural therapy and schema therapy in patients with borderline personality disorder: a secondary analysis of a randomised clinical trial

Nele Assmann, Tim Kaiser, Philipp Herzog, Arnoud Roger Arntz, Jan Philipp Klein et al. (7 authors)

Refubium (Universitätsbibliothek der Freien Universität Berlin)2025-01-01

10.17169/refubium-50835

The Effectiveness of Dialectical Behavior Therapy Compared to Schema Therapy for Borderline Personality Disorder: A Randomized Clinical Trial

Nele Assmann, Anja Schaich, Arnoud Arntz, Till Wagner, Philipp Herzog et al. (12 authors)

Psychotherapy and Psychosomatics2024-07-1015 citations

10.1159/000538404

The societal cost of treatment-seeking patients with borderline personality disorder in Germany.

Wagner T, Assmann N, Köhne S, Schaich A, Alvarez-Fischer D, Borgwardt S, Arntz A, Schweiger U, Fassbinder E.

2021-10-0425 citations

10.1007/s00406-021-01332-1

PRO*BPD: effectiveness of outpatient treatment programs for borderline personality disorder: a comparison of Schema therapy and dialectical behavior therapy: study protocol for a randomized trial.

Fassbinder E, Assmann N, Schaich A, Heinecke K, Wagner T, Sipos V, Jauch-Chara K, Hüppe M, Arntz A, Schweiger U.

2018-10-1918 citations

10.1186/s12888-018-1905-6

Interventions

Group 1: Intensive outpatient treatment program of ST with one individual and one group session per week for 1.5 years Group 2: Intensive outpatient treatment program of DBTwith one individual and one

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Primary DSM-IV diagnosis of BPD (diagnosed by SCID-II interview) Severity of BPD > 20 points in the BPDSI interview (this is a empirically derived severity criterion, distinguishing BPD pathology from other PD-pathology) Willingness to participate in the study (informed consent) Willingness and ability to remain for 1.5 years in the study and to participate reliably in therapy (no relocation plans etc.)

Exclusion criteria

Exclusion criteria: Major psychotic disorder (lifetime diagnosis Intellectual deficits (IQ<85) Inadequate German language skills Acute serious substance dependencies (DSM-IV) that cause severe cognitive restrictions during therapy and which calls for detoxification treatment. Participation is possible after detox treatment and a four weeks abstinence period.

Design outcomes

Primary

Measure	Time frame
Change in BPD symptom severity assessed with the mean score of the Borderline-Personality Disorder Severity Index at 1 year follow up.	—

Secondary

Measure	Time frame
Change in quality of life measured with EQ-5D and WHOQoL, social functioning and participation measured with GAF-SOFAS, Cost-effectiveness measured with a COST-Interview, comorbidity (SKID I and II), general psychiatric symptoms (BSI, QIDS), other measures of BPD-psychopathology (dissociation, emotion regulation skills, experiential avoidance) at one year follow-up.	—

Countries

Germany

Contacts

Public ContactEva Faßbinder

Klinik für Psychiatrie und Psychotherapie, Universität zu Lübeck

eva.fassbinder@uksh.de0451-50098702

Outcome results

None listed